合作伙伴关系的力量：赛诺菲和DNDI创新发展和提供反车道治疗

（3BL Media / The金博宝手机版网页csrfeed）2012年2月8日 -在非洲，疟疾会影响经济，成年人工作的能力以及儿童上学的能力。但主要是杀手。作为非洲儿童死亡率的主要原因，疟疾导致5岁以下儿童的16％死亡（比全球9％），非洲儿童每45秒死亡。为了帮助与疟疾作斗争，非营利性药物研发组织被忽视的疾病倡议（DNDI）和赛诺菲开发了ASAQ®Winthrop（1），这是一种新的组合治疗，以公共实体的优惠价格出售。

疟疾是一种通过雌性蚊子的咬伤从人到人传播的寄生虫病。根据世界卫生组织（WHO）发表的世界疟疾报告，该疾病在2010年在全球范围内造成655,000人死亡。这代表每天近1,800人死亡，其中近90％发生在非洲。2001年，WHO建议使用基于敏捷的联合疗法（ACT）来治疗非洲和亚洲的简单疟疾。谁在依从性和易用性，抵抗控制以及减少转移以及可能降低成本的方面，认为这是高度理想的。三年后，DNDI和SANOFI建立了公私伙伴关系，目的是开发非致敬的固定剂量组合，将敏捷的固定剂量组合组合，以更好地满足患者的需求，尤其是儿童的需求。合作的结果：Asaq Winthrop，每天1或2片固定剂量组合的疟疾治疗。Asaq Winthrop片也可以溶解在水中。为了确保尽可能多的患者可以访问Asaq Winthrop，Sanofi制定了差异化的定价政策。这意味着，对于政府和非政府组织等公共实体，该药物以优惠的价格出售，包括“无损益”价格低于一美元的成年人和50美分的儿童。同样的药物以不同的品牌名称出售给批发商，这些批发商的价格根据该国的价格有所不同。 In addition, Sanofi and DNDi did not seek patent protection, to make the new medicine widely available to those patients in greatest need. In early 2012, ASAQ Winthrop was registered in 29 sub-Saharan African countries, in Colombia and in India with more than 120 million treatments distributed in 21 countries, enabling the treatment of over 120 million malaria attacks. The speed at which ASAQ Winthrop was adopted in the field demonstrates that the drug corresponds to the needs of patients as well as health authorities. It also illustrates the power of partnerships combining different sets of strengths and skills, evolving to include additional stakeholders to meet new global health challenges for poverty-related diseases. Sanofi believes that development and delivery of drugs is not enough. Our Access to Medicines department works with stakeholders in the field to develop a number of training and informational tools about malaria. These educational efforts raise awareness about malaria prevention, diagnosis and treatment by using means adapted to all stakeholders within the healthcare chain. (1) ASAQ®Winthrop在美国未获得批准，因为疟疾不是该国普遍存在的疾病。Sano20636